Glycine transporter2 inhibitors: Getting the balance right
Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity gly...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Vandenberg, Robert J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Reply - Meyer, Jay J. ELSEVIER, 2017, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:98 ; year:2016 ; pages:89-93 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.neuint.2015.12.007 |
|---|
| Katalog-ID: |
ELV02964688X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV02964688X | ||
| 003 | DE-627 | ||
| 005 | 20230623202144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuint.2015.12.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016007000030.pica |
| 035 | |a (DE-627)ELV02964688X | ||
| 035 | |a (ELSEVIER)S0197-0186(15)30076-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 |a 540 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.95 |2 bkl | ||
| 100 | 1 | |a Vandenberg, Robert J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glycine transporter2 inhibitors: Getting the balance right |
| 264 | 1 | |c 2016 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. | ||
| 650 | 7 | |a Pain |2 Elsevier | |
| 650 | 7 | |a Glycine transport |2 Elsevier | |
| 650 | 7 | |a Glycine transport inhibitors |2 Elsevier | |
| 650 | 7 | |a Glycine neurotransmission |2 Elsevier | |
| 700 | 1 | |a Mostyn, Shannon N. |4 oth | |
| 700 | 1 | |a Carland, Jane E. |4 oth | |
| 700 | 1 | |a Ryan, Renae M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Meyer, Jay J. ELSEVIER |t Reply |d 2017 |g Amsterdam [u.a.] |w (DE-627)ELV001600346 |
| 773 | 1 | 8 | |g volume:98 |g year:2016 |g pages:89-93 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.neuint.2015.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.95 |j Augenheilkunde |q VZ |
| 951 | |a AR | ||
| 952 | |d 98 |j 2016 |h 89-93 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r j v rj rjv |
|---|---|
| matchkey_str |
vandenbergrobertjmostynshannonncarlandja:2016----:lcntasotrihbtrgtig |
| hierarchy_sort_str |
2016 |
| bklnumber |
44.95 |
| publishDate |
2016 |
| allfields |
10.1016/j.neuint.2015.12.007 doi GBVA2016007000030.pica (DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 DE-627 ger DE-627 rakwb eng 610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Vandenberg, Robert J. verfasserin aut Glycine transporter2 inhibitors: Getting the balance right 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier Mostyn, Shannon N. oth Carland, Jane E. oth Ryan, Renae M. oth Enthalten in Elsevier Science Meyer, Jay J. ELSEVIER Reply 2017 Amsterdam [u.a.] (DE-627)ELV001600346 volume:98 year:2016 pages:89-93 extent:5 https://doi.org/10.1016/j.neuint.2015.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.95 Augenheilkunde VZ AR 98 2016 89-93 5 045F 610 |
| spelling |
10.1016/j.neuint.2015.12.007 doi GBVA2016007000030.pica (DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 DE-627 ger DE-627 rakwb eng 610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Vandenberg, Robert J. verfasserin aut Glycine transporter2 inhibitors: Getting the balance right 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier Mostyn, Shannon N. oth Carland, Jane E. oth Ryan, Renae M. oth Enthalten in Elsevier Science Meyer, Jay J. ELSEVIER Reply 2017 Amsterdam [u.a.] (DE-627)ELV001600346 volume:98 year:2016 pages:89-93 extent:5 https://doi.org/10.1016/j.neuint.2015.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.95 Augenheilkunde VZ AR 98 2016 89-93 5 045F 610 |
| allfields_unstemmed |
10.1016/j.neuint.2015.12.007 doi GBVA2016007000030.pica (DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 DE-627 ger DE-627 rakwb eng 610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Vandenberg, Robert J. verfasserin aut Glycine transporter2 inhibitors: Getting the balance right 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier Mostyn, Shannon N. oth Carland, Jane E. oth Ryan, Renae M. oth Enthalten in Elsevier Science Meyer, Jay J. ELSEVIER Reply 2017 Amsterdam [u.a.] (DE-627)ELV001600346 volume:98 year:2016 pages:89-93 extent:5 https://doi.org/10.1016/j.neuint.2015.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.95 Augenheilkunde VZ AR 98 2016 89-93 5 045F 610 |
| allfieldsGer |
10.1016/j.neuint.2015.12.007 doi GBVA2016007000030.pica (DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 DE-627 ger DE-627 rakwb eng 610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Vandenberg, Robert J. verfasserin aut Glycine transporter2 inhibitors: Getting the balance right 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier Mostyn, Shannon N. oth Carland, Jane E. oth Ryan, Renae M. oth Enthalten in Elsevier Science Meyer, Jay J. ELSEVIER Reply 2017 Amsterdam [u.a.] (DE-627)ELV001600346 volume:98 year:2016 pages:89-93 extent:5 https://doi.org/10.1016/j.neuint.2015.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.95 Augenheilkunde VZ AR 98 2016 89-93 5 045F 610 |
| allfieldsSound |
10.1016/j.neuint.2015.12.007 doi GBVA2016007000030.pica (DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 DE-627 ger DE-627 rakwb eng 610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Vandenberg, Robert J. verfasserin aut Glycine transporter2 inhibitors: Getting the balance right 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier Mostyn, Shannon N. oth Carland, Jane E. oth Ryan, Renae M. oth Enthalten in Elsevier Science Meyer, Jay J. ELSEVIER Reply 2017 Amsterdam [u.a.] (DE-627)ELV001600346 volume:98 year:2016 pages:89-93 extent:5 https://doi.org/10.1016/j.neuint.2015.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.95 Augenheilkunde VZ AR 98 2016 89-93 5 045F 610 |
| language |
English |
| source |
Enthalten in Reply Amsterdam [u.a.] volume:98 year:2016 pages:89-93 extent:5 |
| sourceStr |
Enthalten in Reply Amsterdam [u.a.] volume:98 year:2016 pages:89-93 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Augenheilkunde |
| institution |
findex.gbv.de |
| topic_facet |
Pain Glycine transport Glycine transport inhibitors Glycine neurotransmission |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Reply |
| authorswithroles_txt_mv |
Vandenberg, Robert J. @@aut@@ Mostyn, Shannon N. @@oth@@ Carland, Jane E. @@oth@@ Ryan, Renae M. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV001600346 |
| dewey-sort |
3610 |
| id |
ELV02964688X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02964688X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623202144.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.neuint.2015.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016007000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02964688X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0197-0186(15)30076-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.95</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vandenberg, Robert J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Glycine transporter2 inhibitors: Getting the balance right</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine transport</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine transport inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine neurotransmission</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mostyn, Shannon N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carland, Jane E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ryan, Renae M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Meyer, Jay J. ELSEVIER</subfield><subfield code="t">Reply</subfield><subfield code="d">2017</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001600346</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:89-93</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.neuint.2015.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.95</subfield><subfield code="j">Augenheilkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2016</subfield><subfield code="h">89-93</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Vandenberg, Robert J. |
| spellingShingle |
Vandenberg, Robert J. ddc 610 ddc 540 bkl 44.95 Elsevier Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Glycine transporter2 inhibitors: Getting the balance right |
| authorStr |
Vandenberg, Robert J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV001600346 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl Glycine transporter2 inhibitors: Getting the balance right Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission Elsevier |
| topic |
ddc 610 ddc 540 bkl 44.95 Elsevier Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission |
| topic_unstemmed |
ddc 610 ddc 540 bkl 44.95 Elsevier Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission |
| topic_browse |
ddc 610 ddc 540 bkl 44.95 Elsevier Pain Elsevier Glycine transport Elsevier Glycine transport inhibitors Elsevier Glycine neurotransmission |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s n m sn snm j e c je jec r m r rm rmr |
| hierarchy_parent_title |
Reply |
| hierarchy_parent_id |
ELV001600346 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
Reply |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV001600346 |
| title |
Glycine transporter2 inhibitors: Getting the balance right |
| ctrlnum |
(DE-627)ELV02964688X (ELSEVIER)S0197-0186(15)30076-0 |
| title_full |
Glycine transporter2 inhibitors: Getting the balance right |
| author_sort |
Vandenberg, Robert J. |
| journal |
Reply |
| journalStr |
Reply |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
89 |
| author_browse |
Vandenberg, Robert J. |
| container_volume |
98 |
| physical |
5 |
| class |
610 540 610 DE-600 540 DE-600 610 VZ 44.95 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Vandenberg, Robert J. |
| doi_str_mv |
10.1016/j.neuint.2015.12.007 |
| dewey-full |
610 540 |
| title_sort |
glycine transporter2 inhibitors: getting the balance right |
| title_auth |
Glycine transporter2 inhibitors: Getting the balance right |
| abstract |
Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. |
| abstractGer |
Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. |
| abstract_unstemmed |
Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Glycine transporter2 inhibitors: Getting the balance right |
| url |
https://doi.org/10.1016/j.neuint.2015.12.007 |
| remote_bool |
true |
| author2 |
Mostyn, Shannon N. Carland, Jane E. Ryan, Renae M. |
| author2Str |
Mostyn, Shannon N. Carland, Jane E. Ryan, Renae M. |
| ppnlink |
ELV001600346 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.neuint.2015.12.007 |
| up_date |
2024-07-06T21:59:40.589Z |
| _version_ |
1803868627891388416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02964688X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623202144.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.neuint.2015.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016007000030.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02964688X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0197-0186(15)30076-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.95</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vandenberg, Robert J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Glycine transporter2 inhibitors: Getting the balance right</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurotransmitter transporters are targets for a wide range of therapeutically useful drugs. This is because they have the capacity to selectively manipulate the dynamics of neurotransmitter concentrations and thereby enhance or diminish signalling through particular brain pathways. High affinity glycine transporters (GlyTs) regulate extracellular concentrations of glycine and provide novel therapeutic targets for neurological disorders.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine transport</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine transport inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glycine neurotransmission</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mostyn, Shannon N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carland, Jane E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ryan, Renae M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Meyer, Jay J. ELSEVIER</subfield><subfield code="t">Reply</subfield><subfield code="d">2017</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001600346</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:89-93</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.neuint.2015.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.95</subfield><subfield code="j">Augenheilkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2016</subfield><subfield code="h">89-93</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4006147 |